ABBV · News · 20260824N
Guidance / Outlook
AbbVie Inc. · 2026-08-24 · Importance 44 · Surprise 60 · In source text
AbbVie lowered its full-year 2026 adjusted diluted EPS guidance. The reduction reflects the anticipated acquisition of Apogee Therapeutics, although the reported coverage does not provide the acquisition consideration or revised EPS range. Management otherwise maintained a constructive outlook based on portfolio diversification and growth in immunology and neuroscience.
Key facts
- AbbVie lowered full-year adjusted EPS guidance due to the anticipated acquisition of Apogee Therapeutics. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | probable | — | AbbVie lowered full-year adjusted EPS guidance due to the anticipated acquisition of Apogee Therapeutics. |